David R. Epstein Sells 370 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein sold 370 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $53.31, for a total transaction of $19,724.70. Following the transaction, the director now directly owns 27,524 shares of the company’s stock, valued at approximately $1,467,304.44. This trade represents a 1.33 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Tempus AI Price Performance

TEM opened at $69.18 on Thursday. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $79.49. The company’s 50 day simple moving average is $44.32 and its 200 day simple moving average is $48.73. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Analyst Ratings Changes

A number of equities research analysts have commented on TEM shares. Loop Capital lowered their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. TD Cowen reaffirmed a “buy” rating and set a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a research note on Wednesday. Piper Sandler reissued a “neutral” rating and issued a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and upped their target price for the company from $45.00 to $65.00 in a report on Monday, November 11th. Finally, Wolfe Research started coverage on shares of Tempus AI in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, Tempus AI has a consensus rating of “Moderate Buy” and a consensus price target of $58.55.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds have recently made changes to their positions in the stock. ARK Investment Management LLC increased its holdings in shares of Tempus AI by 132.1% during the 4th quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company’s stock worth $186,343,000 after buying an additional 3,141,487 shares during the last quarter. NEA Management Company LLC grew its position in Tempus AI by 17.8% during the third quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock valued at $304,846,000 after acquiring an additional 813,169 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its stake in Tempus AI by 166.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company’s stock worth $109,352,000 after acquiring an additional 2,021,394 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Tempus AI by 1.0% in the 3rd quarter. Franklin Resources Inc. now owns 811,311 shares of the company’s stock worth $45,920,000 after purchasing an additional 8,387 shares during the period. Finally, Millennium Management LLC acquired a new position in shares of Tempus AI in the 2nd quarter valued at about $8,067,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.